Abstract
This trial indicates the potential advantages of using a combination of vasoactive agents. In this case, the combination of vasoactive intestinal polypeptide (VIP) and phentolamine would appear to offer the advantage of the erection quality of alprostadil in the absence of compliance-limiting pain at the site of injection.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
8.1 Key Trial References
8.1.1 Major Publication
Sandhu D, Curless E, et al. A double-blind, placebo controlled study of intracavernosal vasoactive intestinal polypeptide and phentolamine mesylate in a novel auto-injector for the treatment of nonpsychogenic erectile dysfunction. Int J Impot Res 11:81–97, 1999.
8.1.2 Other Important Publications
Gerstenberg T, Metz P, et al. Intracavernous self-injection with vasoactive intestinal polypeptide and phentolamine in the management of erectile failure. J Urol 147(5):1277–1279, 1992.
McMahon C. A pilot study of the role on intracavernous injection of vasoactive intestinal polypeptide (VIP) and phentolamine mesylate in the treatment of erectile dysfunction. Int J Impot Res 8(4): 233–236, 1996.
Dinsmore W, Alderdice D. Vasoactive intestinal polypeptide and phentolamine mesylate by autoinjector in the treatment of patients with erectile dysfunction resistant to other intracavernosal agents. Br J Urol 81(3):437–440, 1998.
Dinsmore W, Gingell C, et al. Treating men with predominantly nonpsychogenic erectile dysfunction with intracavernosal vasoactive intestinal polypeptide and phentolamine mesylate in a novel autoinjector system: a multicentre double-blind placebo-controlled study. BJU Int 83(3):274–270, 1999.
Rights and permissions
Copyright information
© 2007 Springer-Verlag London Limited
About this chapter
Cite this chapter
(2007). Evaluation of Novel Combination (Vasoactive Intestinal Polypeptide and Phentolamine) as Intracavernosal Therapy. In: Key Clinical Trials in Erectile Dysfunction. Springer, London. https://doi.org/10.1007/978-1-84628-428-1_8
Download citation
DOI: https://doi.org/10.1007/978-1-84628-428-1_8
Publisher Name: Springer, London
Print ISBN: 978-1-84628-427-4
Online ISBN: 978-1-84628-428-1
eBook Packages: MedicineMedicine (R0)